Effective January 1, 2026, Brazil’s regulatory body, ANVISA, has implemented its new "Regulatory Agenda" which prioritizes aesthetic devices. A key focus for 2026 is the regularization of products for dermal action and the revision of software-as-a-medical-device (SaMD) standards. This move is designed to purge the market of low-quality, "gray market" fillers and uncertified energy devices.

A major 2026 update for international manufacturers is the proposed requirement for MDSAP (Medical Device Single Audit Program) certification for non-domestic firms. This rigorous standard ensures that devices imported into Brazil meet global quality and safety benchmarks. For consumers, these 2026 regulations mean a safer environment; for the market, it creates a "Trust Premium" that allows certified clinics to charge higher rates for guaranteed authentic treatments.

FAQ:

• Question: What is ANVISA’s priority in 2026?

• Answer: Updating the framework for dermal products and tightening the rules for aesthetic software and tattoo pigments.

• Question: What is the MDSAP requirement?

• Answer: A requirement for international manufacturers to have a single, global-standard audit to sell medical devices in Brazil.